Compare Incyte Corporation (INCY) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sezzle Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Sezzle Inc trades at $127.04 (market cap $3.95B). The key difference: Incyte Corporation is far larger — about 5.8× Sezzle Inc's market cap, and Sezzle Inc is more actively traded (550,075 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Sezzle Inc for 15 Days on average.
| INCY | SEZL | |
|---|---|---|
Market Cap | $22.85B | $3.95B |
Volume | 1,927,029 | 550,075 |
Sector | Health | Financials |
52-Week High | $129.93 | $188.55 |
52-Week Low | $83.80 | $50.97 |
Typical Hold Time | 33 Days | 15 Days |
Enterprise Value | $18.35B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
SEZL stock trades at $126.61, up 11.21% with strong bullish momentum. The company demonstrates exceptional profitability with 30.35% net income margin and 88.85% ROE, supported by 51.7% revenue growth in Q2 2026. Technical indicators show bullish signals with current price above key support levels, while analyst consensus targets $168.00 representing 32.7% upside potential. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents compelling growth prospects with robust fundamentals and positive analyst sentiment, though elevated valuation multiples and competitive BNPL market dynamics warrant monitoring. The stock's current technical strength combined with strong earnings beats and institutional accumulation supports continued upside potential, while investors should consider the stock's premium valuation relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
